![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Inozyme Pharma Inc is a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue and skeleton. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 ... Inozyme Pharma Inc is a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue and skeleton. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies. Its product candidate, INZ-701, is a soluble, recombinant, or genetically engineered, fusion protein that is designed to correct a defect in the mineralization pathway caused by ENPP1 and ABCC6 deficiencies. Show more
ROCHESTER, N.Y., June 30 /PRNewswire/ -- TBCToday.com is pleased to offer its stock alerts service to the investing community. Investors who are interested in stocks on the move and in the news...
NEW YORK, Aug. 23 /PRNewswire/ -- The American Stock Exchange(R) (Amex(R)) will begin trading end of quarter expiration options on Thursday, August 24, 2006 on the following ETFs. * Energy...
CHICAGO, Dec. 8 /PRNewswire-FirstCall/ -- Archipelago Holdings, Inc. (PCX:AX) today announced its November 2005 market transaction volume data for the Archipelago Exchange (ArcaEx(R)) and the...
SAN FRANCISCO, Nov. 3 /PRNewswire-FirstCall/ -- The Pacific Exchange, Inc. ("PCX") announced that at the opening of business on Thursday, November 3, 2005, it will commence trading options on...
WallSt.net Airing Exclusive Audio Interviews With GDVI and XLE NEW YORK, June 2 /PRNewswire/ -- Phil Hamilton, CEO of Global Diversified Industries, Inc. (OTC:GDVI) (BULLETIN BOARD: GDVI...
WallSt.net Airing Exclusive Audio Interviews With WYSK and XLE NEW YORK, March 2 /PRNewswire/ -- Daniel Moar, CEO of Wysak Petroleum, Inc. (Pink Sheets: WYSK) recently granted Wall Street Network...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.37 | 6.89013035382 | 5.37 | 5.97 | 5.2024 | 202401 | 5.72581585 | CS |
4 | 1.29 | 28.9887640449 | 4.45 | 5.97 | 4.32 | 275707 | 5.13414716 | CS |
12 | 0.94 | 19.5833333333 | 4.8 | 5.97 | 4.24 | 325581 | 4.75469866 | CS |
26 | 1.02 | 21.6101694915 | 4.72 | 7.795 | 4.18 | 514628 | 5.48628775 | CS |
52 | 0.82 | 16.6666666667 | 4.92 | 7.795 | 2.689 | 512954 | 4.86697022 | CS |
156 | -11.45 | -66.6084933101 | 17.19 | 17.8 | 0.991 | 428864 | 4.47196888 | CS |
260 | -12.19 | -67.9866146124 | 17.93 | 31.6499 | 0.991 | 336215 | 5.33592048 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions